Reuters logo
BRIEF-Pharmaxis says Boehringer confirms phase 2 study for second disease indication will commence this year
May 14, 2017 / 11:54 PM / 6 months ago

BRIEF-Pharmaxis says Boehringer confirms phase 2 study for second disease indication will commence this year

May 15 (Reuters) - Pharmaxis Ltd

* In addition to a phase 2 trial in Nash that is scheduled to start mid‐year, Boehringer has confirmed that a phase 2 study for a second disease indication will commence this year Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below